Literature DB >> 19144670

Fibrates: where are we now?

Rohit Seth Loomba1, Rohit Arora.   

Abstract

UNLABELLED: Cardiovascular disease remains a leading cause of mortality worldwide. As dyslipidemia increases cardiovascular disease risk, proper management of dyslipidemia is one means by which to decrease cardiovascular disease risk. This review focuses on dyslipidemia treatment utilizing fibrate therapy, which targets high trigylcerides, low HDL, and high small, dense LDL, while contrasting fibrate therapy with statin therapy and combined therapy. Studies were obtained using electronic search strategies, such as Medline and Cochrane Library. Sources selected were limited to those that discussed fibrates, statins, and combined therapy, with specific emphasis placed on sources that focused on fibrates. Selected studies were then assessed for quality via analysis of the study's methodology, results, and data.
RESULTS: of selected studies were then stratified using a rating system devised to determine the quality of results using the scientific evidence provided for them. Combination fibrate and statin therapy can be more effective in achieving optimal lipid levels than just fibrate or statin therapy alone without significant side effects as long as gemfibrozil is not used in therapy.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19144670     DOI: 10.1177/1753944708096281

Source DB:  PubMed          Journal:  Ther Adv Cardiovasc Dis        ISSN: 1753-9447


  2 in total

1.  Nutritional and metabolic status of HIV-positive patients with lipodystrophy during one year of follow-up.

Authors:  Eloísa Marchi Dos Anjos; Karina Pfrimer; Alcyone Artioli Machado; Selma Freire de Carvalho Cunha; Roberta Garcia Salomão; Jacqueline Pontes Monteiro
Journal:  Clinics (Sao Paulo)       Date:  2011       Impact factor: 2.365

2.  Peroxisome Proliferator-Activated Receptor delta: A Target with a Broad Therapeutic Potential for Drug Discovery.

Authors:  Francine M Gregoire
Journal:  PPAR Res       Date:  2009-04-07       Impact factor: 4.964

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.